Medicare Negotiations And Patent Cliffs Will Stifle Revenues
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 19 Analysts
Published
06 May 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$18.37
35.9% overvalued intrinsic discount16 Aug
US$24.97
1Y
60.4%7D
-1.9%